Abstract Details

Title Incidence Trends of Early-Onset Parkinson’s Disease in Olmsted County, MN: 1976-2013.

Topic Neuroepidemiology

Presentation(s) S12 - Neuroepidemiology (1:24 PM-1:36 PM)

Poster/Presentation
Number 003

Background Few studies investigated the trends of incidence of EOPD.

Objective To determine 38-year incidence trends and survival of early-onset Parkinson disease (EOPD) in Olmsted County, MN.

Design/Methods We used the Rochester Epidemiology Project to define a population-based cohort of EOPD from 1976-2013 in Olmsted County, MN. A movement disorder specialist reviewed all the clinical records to confirm the diagnosis of PD. To define EOPD, we used two cut-off ages of 50 and 55 years of age.

Results

EOPD incidence was 1.52/100,000 person-years for the ≤55 group, and 0.60/100,000 person-years when the cut-off was ≤50 years of age. Men had higher incidence than women in both age groups (1.98 vs 1.09; and 0.70 vs 0.50). The incidence of EOPD diagnosed before the age of 55 increased each decade: from 0.99/100.000 person-year between 1976-1985, to 1.71/100.000 person-year between 2006-2013. A similar trend was observed in the incidence of EOPD divided by decades for the group of patients diagnosed ≤50 years of age (0.26/100,000 person-years in 1976-1985, to 0.82/100,000 person-year in 2006-2013). Incidence was higher in men than women in each decade with the exception of 2006-2013 in the EOPD group diagnosed before the age of 50.
Median time from EOPD symptom onset to death was not significantly different between sexes, for both EOPD ≤55 (21.0 years in men vs 22.1 years in women, p= 0.97) and EOPD ≤50 (20.4 in men vs 19.8 in women, p= 0.86).

Conclusions We observed an increase in the incidence of EOPD over a 40-year span; this may be secondary to better recognition by physicians and/or improved diagnostic tools but can be also caused by differences in environmental exposures and risk factors.

Authors/Disclosures
Emanuele Camerucci, MD (Kansas University Medical Center) PRESENTER	Dr. Camerucci has nothing to disclose.
Aidan Mullan (Mayo Clinic)	No disclosure on file
Pierpaolo Turcano, MD (Mayo Clinic)	Dr. Turcano has nothing to disclose.
Cole D. Stang	Mr. Stang has nothing to disclose.
	No disclosure on file
Bradley F. Boeve, MD, FAAN (Mayo Clinic)	Dr. Boeve has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Rainwater Charitable Foundation. The institution of Dr. Boeve has received research support from Alector. The institution of Dr. Boeve has received research support from EIP Pharma. The institution of Dr. Boeve has received research support from Transposon. The institution of Dr. Boeve has received research support from Cognition Therapeutics. Dr. Boeve has received publishing royalties from a publication relating to health care.
James H. Bower, MD, MSc, FAAN (Mayo Clinic)	The institution of Dr. Bower has received research support from Abbvie.
J. E. Ahlskog, MD, PhD (Mayo Clinic)	Dr. Ahlskog has received publishing royalties from a publication relating to health care.
Rodolfo Savica, MD, PhD, FAAN (Mayo Clinic)	The institution of Dr. Savica has received research support from ACADIA Pharmaceuticals, Inc.